Drugs / Cyproheptadine
Cyproheptadine
also known as
cyproheptadine hydrochloride · Ciproheptadina · Ciprovit · CPH · CYPRO · Cyproheptadine hcl · Cyproheptadine hydrochloride hydrate · Cyproheptadine hydrochloride sesquihydrate · +6 more
Small molecule targets HRH1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PERIACTIN | — | 1961-10-17 | fda.gov ↗ |
Trials 18
19601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06147622 | Apr → Jul 2024 | alcohol-related disorders | Kinnov Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05708274 | Jan 2023 → Oct 2025 | spinal cord injury | Bronx VA Medical Center | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05469165 | Jun 2023 → Sep 2026 overdue | mitral valve insufficiency | Laval University | Recruiting | No outcome recorded |
| Phase 2 | NCT04876573 | Jun → Dec 2021 | platelet disorder, undefined, serotonin syndrome, viral pneumonia | Ciusss de L'Est de l'Île de Montréal | Unknown | No outcome recorded |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | Missed primary |
| Phase 2 | NCT04108104 | Nov 2019 → Oct 2021 | alcohol dependence | Kinnov Therapeutics | Completed | Met primary |
| Phase 2 | NCT01675050 | Aug 2012 → Aug 2013 | — | University of Michigan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00949117 | Sep 2009 → Nov 2011 | childhood malignant neoplasm, leukemia, lymphoma, myelodysplastic syndrome +1 | University of South Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00066248 | Jun 2003 → Aug 2007 | childhood malignant neoplasm, hypoproteinemia, hypercatabolic, leukemia, lymphoma +3 | University of South Florida | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06175273 | Jan 2024 → Aug 2025 | childhood malignant neoplasm, muscular atrophy, nutritional deficiency disease | Corey Hawes | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04979221 | Jul 2021 → Jan 2022 | pneumonia | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 3 | NCT04820751 | Apr → Nov 2021 | platelet disorder, undefined, serotonin syndrome, viral pneumonia | Ciusss de L'Est de l'Île de Montréal | Unknown | No outcome recorded |
| Phase 3 | NCT01132547 | Jun 2010 → Jan 2014 | cancer | University of South Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT06751290 | Dec 2024 → Apr 2026 | avoidant/restrictive food intake disorder | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT05087381 | Oct 2021 → Jun 2022 | — | Chulalongkorn University | Completed | Met primary |
| Phase 4 | NCT02568007 | Dec 2015 → Aug 2016 | — | Medical College of Wisconsin | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable2 trials · 1 met primary | ||||||
| — | NCT07006181 | Nov 2024 → Feb 2025 | — | Indonesia University | Completed | No outcome recorded |
| — | NCT02418949 | Nov 2015 → Aug 2019 | hemiplegia, stroke disorder | Shirley Ryan AbilityLab | Completed | Met primary |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT03593811 Comparator | Aug 2018 → Apr 2021 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT01688570 Comparator | Aug 2011 → May 2015 | stroke disorder | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 3 | NCT01295450 Comparator | Apr → Aug 2011 | eating disorder | MDCPharma Produtos Farmaceuticos LTDA | Unknown | No outcome recorded |
| Phase 4 | NCT01940978 Comparator | Mar 2014 → Mar 2015 | attention deficit-hyperactivity disorder | Douglas Sears | Completed | No outcome recorded |
| Phase 4 | NCT01314989 Comparator | Dec 2010 → Mar 2011 | — | St. Justine's Hospital | Unknown | No outcome recorded |
| — | NCT05753774 Comparator | Aug 2022 → Aug 2026 overdue | — | Biao Zou | Recruiting | No outcome recorded |
| — | NCT01538693 Comparator | Dec 2011 → May 2015 | spinal cord injury | T. George Hornby | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-07-14 | Lannett Company, Inc. | Lannett Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL investorroom.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyproheptadine | “A single dose of Cyproheptadine (CPH) (8 mg) will be administered.” NCT05708274 ↗ |
| Known as | Ciproheptadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | Ciprovit | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | CPH | “A single dose of Cyproheptadine (CPH) (8 mg) will be administered.” NCT05708274 ↗ |
| Known as | CYPRO | “cyproheptadine (CYPRO), a 5HT antagonist” NCT01538693 ↗ |
| Known as | Cyproheptadine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | cyproheptadine hydrochloride | “Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg,...” NCT01295450 ↗3“Cyproheptadine hydrochloride (CH), an appetite stimulant, was administered to children with cancer-associated cachexia to prevent further weight loss.” PMID 18989154 ↗ Nov 2008 “RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment.” NCT01132547 ↗ |
| Known as | Cyproheptadine hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | Cyproheptadine hydrochloride sesquihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | Cyproheptadine hydrocloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | NSC-169911 | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | NSC-759282 | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | Periactin | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | Periactine | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Known as | Peritol | ChEMBL registry synonym — accepted as the source's own label CHEMBL516 ↗ |
| Action | Inhibit | “cyproheptadine (CYPRO), a 5HT antagonist” NCT01538693 ↗1“Histamine H1 receptor antagonist” CHEMBL516 ↗ |
| Modality | Small molecule | — CHEMBL516 ↗ |
| Route | Oral | “Patients receive oral cyproheptadine twice daily for 4 weeks” NCT00066248 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL516 ↗ |